Follow the Money: Pathos AI Drug Development Platform, Stylus Medicine’s In Vivo Advancements, More

Pathos AI announced its $365 million Series D financing. This financing expands Pathos’ AI-enabled platform to drive greater speed, precision, and success in oncology drug development. The proceeds will support advancements of the company’s clinical-stage pipeline and continued investment in its proprietary AI foundation model purpose-built for oncology.

$148M: Series B for Rare Lysosomal Storage Disorders 

Azafaros has raised $148 million in a Series B financing to advance a pipeline of therapies against rare lysosomal storage disorders. With the funds, Azafaros will run two Phase III programs for the investigational small molecule drug nizubaglustat, which is being tested for Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses. The company expects to launch both late-stage trials later this year. In addition, the financing will also be used to expand the company’s pipeline into other projects.

$130M: Series B for Liver-Rejuvenating mRNA Medicine 

NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a $130 million Series B fundraising round. The preclinical company’s lead asset uses lipid nanoparticles to deliver mRNA to liver cells that codes for transcription factors known to make hepatocytes look—and act—younger. The company’s first target is alcohol-related liver disease.

$110M: Series C for Largest-Ever Quantum Software 

Classiq has raised $110 million in Series C funding. The funds position the company to meet growing demand by significantly scaling its go-to-market, customer success, and R&D teams. Classiq’s platform addresses the widening gap between quantum hardware and quantum software with the following features: accelerated onboarding, automated algorithm development that scales, and hardware-agnostic deployment.

$100M: Series A and B for Autoimmune Antibody Treatments 

Granite Bio has secured $100 million in funding for its new antibody treatments that target several autoimmune diseases, with a Series A round of $30 million and a Series B round of $70 million. Granite Bio's pipeline includes two antibodies designed to address various autoimmune conditions. The first molecule, GRT-001, targets pro-inflammatory monocytes, which are pivotal in the development of autoimmunity and inflammation. The second molecule, GRT-002, is designed to inhibit interleukin-3, a significant contributor to autoimmune inflammation, as well as type II inflammation.

$85M: Series A for Precision In Vivo Genetic Medicines 

Stylus Medicine emerged from stealth with $85 million in Series A financing. The proceeds will advance the company’s in vivo genetic medicines platform and pipeline of in vivo therapeutic programs. The company’s engineering platform combines sequence-specific genome integration with cell-targeted lipid nanoparticle (LNP) delivery. The platform is based on Stylus-designed therapeutic-grade recombinases capable of encoding polyfunctional multi-kb payloads with high efficiency, specificity, and fidelity. 

$65M: Series A for Chronic and Age-Related Diseases Medicines 

HAYA Therapeutics has raised $65 million in Series A funding. The finances will accelerate the clinical development of HAYA’s lead long non-coding RNA (lncRNA) targeting candidate HTX-001 in heart failure and the continued expansion of its RNA-guided regulatory genome pipeline development engine.

$57M: Series C for Direct-From-Blood Rapid Pathogen Detection 

deepull announced the successful closing of an oversubscribed Series C financing round of $57 million. Proceeds will be deployed to finalize clinical validation and expedite the regulatory approval process of deepull’s UllCORE diagnostic system, which received Breakthrough Device Designation from the FDA in December 2024. UllCORE is a fully automated system, which uses molecular techniques to extract and detect microbial DNA directly from whole blood. The multiplex PCR test covers 95% of sepsis-causing pathogens, including bacteria and fungi, as well as antibiotic resistance genes, providing critical results to caregivers in about one hour.

$52M: Series B for Glioblastoma Therapy 

Alpheus Medical announced the closing of an oversubscribed $52 million Series B financing round. The funds will support a Phase 2B randomized controlled trial (RCT) evaluating the efficacy of SDT in patients with newly diagnosed glioblastoma (GBM), one of the most aggressive and deadly forms of brain cancer.

$50M: Series A for Supercharge AI for Clinical Development 

PhaseV announced the completion of a $50 million Series A funding round. The funding will allow PhaseV to grow its vertical AI platform to provide holistic solutions for clinical development. PhaseV's vertical AI platform supports end-to-end clinical development from design through execution. It currently comprises four core applications: Trial Optimizer for optimizing and implementing Bayesian, adaptive, and fixed trials; Causal ML for heterogeneous treatment effect estimation to uncover hidden signals in clinical data and identify subpopulations and endpoints with the highest potential for success; Causal Disease Modeling to inform new R&D and life cycle management; and Clinical Operations for Causal ML-driven site selection, site performance analytics, real-time trial progress monitoring, and integration of virtual control arms.

$47M: Series A for AI Foundation Models for Human Cell Therapy Development 

Somite AI closed a $47 million Series A funding round. Somite AI is building DeltaStem, a platform and foundation model designed to revolutionize the production of human cells. This funding enables Somite AI to accelerate key therapeutic programs, including beta cells for type 1 diabetes, articular cartilage for orthopedic applications, satellite cells for muscular diseases, and hematopoietic cells for blood disorders, as well as further develop the capabilities of DeltaStem.

$45M: Series B for Novel Mechanobiology-Centered Therapy for Cardiomyopathy 

Nuevocor closed a $45 million Series B financing round. The new investment will support a first-in-human, open-label, multicenter, ascending single-dose Phase 1/2 clinical trial of NVC-001 in patients with LMNA DCM, with clinical trial sites across the U.S. and Europe. Additionally, the company will establish an office in Paris, France, to support clinical development and bring Singapore innovation to patients globally.

$39M: Series B for KRAS-Driven Cancers with High Unmet Need 

PAQ Therapeutics announced the completion of its $39 million Series B funding. The capital raised will fund PAQ's next stage of clinical development for the company's lead asset PT0253, a potent and selective degrader of KRAS G12D, a known driver for a range of solid tumors. PT0253 has demonstrated potential based on preclinical comparison to existing agents currently in clinical development targeting the same KRAS mutant.

$30M: Series A for Novel Therapeutic Modality 

Grove Biopharma closed a $30 million Series A financing. Proceeds will be used to further advance Grove Biopharma’s proprietary platform Bionic Biologics and drive its lead oncology programs towards the clinic. The platform represents a novel therapeutic modality that integrates principles of biologic and synthetic design. This platform enables the targeting of well-validated yet previously intractable disease drivers, unlocking new possibilities for therapeutic intervention.

$25.6M: Series B for Ovarian Cancer Trial 

TILT Biotherapeutics has raised $25.6 million in Series B financing. The funds will support a Phase 2 clinical trial of Tiltbio’s lead product, TILT-123, in patients with platinum-resistant epithelial ovarian cancer, a Phase 1b trial in melanoma in combination with TILs and other Phase 1b trials. TILT-123 (Igrelimogene litadenorepvec), an oncolytic adenovirus armed with tumor necrosis factor (TNF) and interleukin-2 (IL-2), is designed to enhance the efficacy of T-cell therapies and immune checkpoint blockade.

$25M: Series A for Small Molecule Drug Discovery AI Platform 

Inductive Bio has raised $25 million in Series A financing. The funds will expand Inductive’s AI model R&D, grow its pre-competitive data consortium and deploy its technology industry-wide, leveling the playing field for both innovative startups and large pharmaceutical companies. Longer-term, Inductive aims to launch an AI-native contract research organization (CRO) on top of this technology.

$18.2M: Series B for AI-Powered Clinical Data Abstraction and Analytics 

Carta Healthcare has secured $18.25 million in Series B1 financing. The proceeds will be used for the company's growth as demand surges among health systems and life sciences organizations for AI-driven innovation that can transform clinical data into valuable insights. The funds will also enable Carta Healthcare to further expand its growing customer footprint, particularly in the life sciences market, following the late 2024 acquisition of Realyze Intelligence from UPMC Enterprises.

$12M: Series A for AI-Driven Robotics Platform 

Persist AI announced the launch of its innovative Cloud Lab platform following the successful closure of an oversubscribed $12 million Series A financing round. The new platform allows pharmaceutical companies to develop formulations using Persist AI's state-of-the-art robotic laboratory facilities through a website, dramatically accelerating drug development timelines while using a fraction of the materials required by traditional methods.

$12M: Seed Financing for Next-Gen Regenerative Medicines 

Stately Bio announced $12 million in seed financing. The company will use the new funding to scale its platform technology and mature its internal pipeline of stem cell-derived therapeutics. A major bottleneck in the development and production of cell therapies is the reliance on destructive approaches to understand cell state. Stately Bio’s technology removes the need to choose between measuring cells and keeping them alive. The company’s ML-driven imaging platform identifies and monitors cells in real time using only label-free, live-cell compatible imaging, with no need for fluorescent tags or genetic modification.

$8M: Seed Financing for Whole Lab Automation 

Trilobio announced it has raised $8 million seed financing. The proceeds will support the expansion of the Trilobio Platform’s robotics capabilities and no-code software features, enabling a growing portfolio of purpose-built lab devices and protocols to be integrated into a single, fully automated platform. Trilobio offers an accessible and scalable solution to transform genetic engineering, synthetic biology, and life science research processes.

$7.5M: Series A for AI-Powered Pathology Platform 

Gestalt announced the completion of a $7.5 million Series A financing. Gestalt's PathFlow platform integrates into customers’ existing laboratory information systems, enabling faster, more accurate diagnoses and improving access to expert consultation, education, and research—regardless of location. The proceeds will be used to expand the company's customer base, enhance AI capabilities, and pursue FDA clearance.